Equities

Mangalam Drugs and Organics Ltd

MANGALAM:NSI

Mangalam Drugs and Organics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)128.98
  • Today's Change1.48 / 1.16%
  • Shares traded34.25k
  • 1 Year change+27.32%
  • Beta1.1853
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1010020
Total Receivables, Net699466465
Total Inventory1,2361,3751,171
Prepaid expenses17----
Other current assets, total35126169
Total current assets1,9982,0661,825
Property, plant & equipment, net1,2651,3361,268
Goodwill, net------
Intangibles, net285183139
Long term investments0.350.040.04
Note receivable - long term228.8024
Other long term assets0.903.0829
Total assets3,5713,5963,284
LIABILITIES
Accounts payable831971545
Accrued expenses31----
Notes payable/short-term debt746496471
Current portion long-term debt/capital leases126135105
Other current liabilities, total7752180
Total current liabilities1,8101,6541,301
Total long term debt185255343
Total debt1,056885918
Deferred income tax121145135
Minority interest------
Other liabilities, total33230.01
Total liabilities2,1482,0771,779
SHAREHOLDERS EQUITY
Common stock158158158
Additional paid-in capital224224224
Retained earnings (accumulated deficit)1,0411,1381,124
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,4231,5201,506
Total liabilities & shareholders' equity3,5713,5963,284
Total common shares outstanding161616
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.